Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.6431 -0.0237 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
BioXcel Therapeutics Inc. (NASDAQ: BTAI) Near the Top of Equities by Percentage Gain on 7/5
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell... 
Via Benzinga
Analyst Expectations for BioXcel Therapeutics's Future
Via Benzinga
Goldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To Know
Via Benzinga
Where BioXcel Therapeutics Stands With Analysts
Via Benzinga
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to... 
Via Benzinga
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
From Gibbs Law Group
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P... 
Via Benzinga
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Up Triple Digits After Bank Stress Test, GDP Revision
The Dow Jones Industrial Average is up 194 points midday, while the S&P 500 Index and Nasdaq Composite move cautiously higher. 
Via Talk Markets
Crude Oil Edges Higher; McCormick Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.64% to 34,069.87 while the NASDAQ rose 0.13% to 13,609.09. The S&P... 
Via Benzinga
Why Shares of BioXcel Therapeutics Are Plunging Thursday
Questions regarding the safety of an Alzheimer's disease agitation therapy were raised when the company announced phase 3 trial results. 
Via The Motley Fool
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Are BioXcel Therapeutics Shares Plummeting Today
BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are tumbling after the company released topline results for TRANQUILITY II, a Phase 3 trial of BXCL501 for the acute treatment of  
Via Benzinga
Dow Rises Over 100 Points; US GDP Grows 2% In Q1
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.37% to 33,977.04 while the NASDAQ rose... 
Via Benzinga
FREY Stock Price Prediction: Is Freyr Battery Really Worth $13?
Freyr Battery (FREY) stock is on the move Thursday with heavy trading following positive coverage from analysts at Morgan Stanley. 
Via InvestorPlace
Why Is Cormedix (CRMD) Stock Down 23% Today?
Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! 
Via InvestorPlace
BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society'
The company hopes to soon gain approval to treat patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
If you can’t stand a dull day at the trading desk, these short-squeeze stocks to buy could spike your blood pressure and your portfolio. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.